

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 7,417,041
Issued : Aug. 26, 2008
Serial No. : 10/783,251
Filed : Feb. 20, 2004
Inventors : Blumberg et al.
For : IMIDAZOPYRIMIDINES AS TRANSFORMING GROWTH FACTOR (TGF)
INHIBITORS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Attention: Certificate of Correction Branch

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1.323

Sir:

Applicants noted an error in the definition of R⁴ and R⁶ in claim 1, column 57, line 50 in the published patent, US 7417041. The definitions of R⁴ and R⁶ in claim 1 as originally filed read as “R⁴ and R⁶ taken together with the atoms to which they are attached form a core fused heteraromatic.” Per the amendment on April 20, 2007, and the elected subject matter in the Restriction Requirement dated Nov. 16, 2006, Applicants amended the definitions of R⁴ and R⁶ in claim 1 to read “R⁴ and R⁶ taken together with the atoms to which they are attached form a pyrimidyl moiety.” In a response dated July 23, 2008, to an Office Action, Applicants inadvertently changed the definitions of R⁴ and R⁶ back to the original definitions.

Applicants had discussed the error with the Examiner, Susanna Moore, after realizing the error. The Examiner suggested a Certificate of Correction be submitted to correct the oversight.

The issuance of the Certificate of Correction under 37 CFR 1.323 is respectfully requested.

It is believed that no fees are required for this Certificate of Correction. However, if fees are required, the Commissioner is authorized to charge Deposit Account 16-1445.

Please mail the Certificate of Correction to the undersigned agent.

Respectfully submitted,



Lucy X. Yang

Registration No. 40,259

Date: May 20, 2010

Pfizer Inc.

Patent Department

KZO-300-106SW

7000 Portage Road

Kalamazoo, Michigan 49001

Telephone No. (269) 833-9536

Telefax No. (269) 833-8897

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,417,041

APPLICATION NO.: 10/783,251

ISSUE DATE : Aug. 26, 2008

INVENTOR(S) : Blumberg et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 57, lines 50-51, should read

"R4 and R6 taken together with the atoms to which they are attached form a pyrimidyl moiety."

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Lucy X. Yang
7000 Portage Road
Kalamazoo, MI 49001

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.